Posted in | News | Bionanotechnology

DNA Nanotechnology Paves for New Class of Synthetic Vaccines

Scientists at the Biodesign Institute in Arizona State University have made use of DNA nanotechnology to produce a new group of synthetic vaccines. The team wanted to replicate the assembly of molecules in the body that initiate an immune response.

Synthetic Vaccine Complex (Credit: Biodesign Institute at Arizona State University)

Nanotechnology innovator Hao Yan is credited with the development of DNA nanostructures which could function as scaffolding material. The team at Arizona State University led by Yung Chang worked in collaboration with Hao Yan to test various shapes and sizes of DNA nanostructure for their ability to carry molecules that can trigger an immune response in the body.

The team created synthetic vaccine complexes resembling natural virus without the disease component. These were made of a protein for immune stimulation named streptavidin (STV) and a compound to boost immune response called an adjuvant (CpG oligo-deoxynucletides). These were then attached to DNA nanostructures of pyramid shape and branch-like structures. In order to establish that the nanostructures would be taken in by the target cells in the body, a light-emitting tracer molecule was attached to the DNA nanostructures. The team found that the nanostructures were safely ensconced in cells for a period of time long enough to generate an immune response. The team’s next challenge was to test the delivery of the vaccine to first responder cells in order to check for effective immune response. The experiment was carried out on mice wherein all variables were tested. There were thus three categories, viz. full vaccine complex, STV alone and Mixture of STV and CpG.

Over a period of 70 days, the team found that mice injected with the full vaccine complex developed immune response nine-fold higher than those with CpG and STV mixture and the pyramid shaped structures yielded the best immune response. This holds great potential for the development of targeted therapeutics.

Will Soutter

Written by

Will Soutter

Will has a B.Sc. in Chemistry from the University of Durham, and a M.Sc. in Green Chemistry from the University of York. Naturally, Will is our resident Chemistry expert but, a love of science and the internet makes Will the all-rounder of the team. In his spare time Will likes to play the drums, cook and brew cider.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Arizona State University. (2019, February 12). DNA Nanotechnology Paves for New Class of Synthetic Vaccines. AZoNano. Retrieved on December 11, 2024 from https://www.azonano.com/news.aspx?newsID=25309.

  • MLA

    Arizona State University. "DNA Nanotechnology Paves for New Class of Synthetic Vaccines". AZoNano. 11 December 2024. <https://www.azonano.com/news.aspx?newsID=25309>.

  • Chicago

    Arizona State University. "DNA Nanotechnology Paves for New Class of Synthetic Vaccines". AZoNano. https://www.azonano.com/news.aspx?newsID=25309. (accessed December 11, 2024).

  • Harvard

    Arizona State University. 2019. DNA Nanotechnology Paves for New Class of Synthetic Vaccines. AZoNano, viewed 11 December 2024, https://www.azonano.com/news.aspx?newsID=25309.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.